Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) EPS (Basic) (2020 - 2025)

Gain Therapeutics has reported EPS (Basic) over the past 6 years, most recently at -$0.11 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.11 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was -$0.61 (up 33.7% YoY), and the annual figure for FY2025 was -$0.61, up 31.46%.
  • EPS (Basic) for Q4 2025 was -$0.11 at Gain Therapeutics, up from -$0.15 in the prior quarter.
  • Over the last five years, EPS (Basic) for GANX hit a ceiling of -$0.11 in Q4 2024 and a floor of -$0.62 in Q2 2023.
  • Median EPS (Basic) over the past 5 years was -$0.3 (2021), compared with a mean of -$0.31.
  • Biggest five-year swings in EPS (Basic): plummeted 72.41% in 2021 and later skyrocketed 62.07% in 2024.
  • Gain Therapeutics' EPS (Basic) stood at -$0.26 in 2021, then plummeted by 50.0% to -$0.39 in 2022, then rose by 25.64% to -$0.29 in 2023, then skyrocketed by 62.07% to -$0.11 in 2024, then changed by 0.0% to -$0.11 in 2025.
  • The last three reported values for EPS (Basic) were -$0.11 (Q4 2025), -$0.15 (Q3 2025), and -$0.19 (Q2 2025) per Business Quant data.